IntravenousAcute hypotensive statesAdult: As norepinephrine base: Initially, 0.4-0.8 mg/hour given via infusion. Then titrate dose in steps of 0.05-0.1 mcg/kg/min to maintain normotension or achieve an adequate mean arterial blood pressure depending on patient's condition. Elderly: Initial dose should be at low end of dose range.
|
Intravenous:
Dilute with 5% glucose inj, with or without sodium chloride; dilution with sodium chloride inj alone is not recommended.
|
Intravenous:
Incompatible with alkali and oxidising agents, barbiturates, chlorphenamine, chlorothiazide, nitrofurantoin, novobiocin, phenytoin, sodium bicarbonate, sodium iodide, streptomycin, insulin.
|
Hypertension. Pregnancy. Patients with peripheral or mesenteric vascular thrombosis unless necessary as a life-saving procedure.
|
Not a substitute for replacement of blood, plasma, fluids, and/or electrolytes; correct volume depletion prior to admin. Identify and correct hypoxia, hypercapnia and acidosis prior to or during admin. Avoid extravasation as tissue necrosis may occur. Avoid inj into leg veins, especially in elderly or those with occlusive vascular diseases, arteriosclerosis, DM or Buerger's disease. Hypertensive or hyperthyroid patients. In conjunction with local anaesthetics, do not use in fingers, toes, ears, nose or genitalia. Lactation.
|
Hypertension, headache, peripheral ischaemia, bradycardia, arrhythmias, anxiety, skin necrosis (with extravasation), dyspnoea, respiratory difficulty.
|
|
Symptoms: Hypertension, sweating, cerebral haemorrhage, convulsions.
|
Guanethidine, methyldopa, reserpine, TCAs may increase pressor response to norepinephrine.
Potentially Fatal: Increased risk of arrhythmias with cocaine, cyclopropane or halogenated hydrocarbon anaesthetics. Hypertensive crisis may occur with MAOIs. Hypertensive effects may be increased by nonselective β-blockers.
|
Description: Norepinephrine is a direct-acting sympathomimetic which stimulates β1- and α-adrenergic receptors. Its α-agonist effects cause vasoconstriction, thereby raising systolic and diastolic BP with reflex slowing of heart rate. Onset: Rapid. Duration: Short; stops within 1-2 min after discontinuing the infusion. Pharmacokinetics: Absorption: Oral: Destroyed in the GI tract; SC: Poorly absorbed. Distribution: Mainly localises in sympathetic nervous tissue; crosses the placenta but not the blood-brain barrier. Metabolism: Metabolised in the liver and in other tissues by the enzymes catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Excretion: Via urine (mainly as metabolites).
|
Intravenous:
Store at room temperature (25°C) and protect from light. Store in tight, light-resistant containers as norepinephrine is readily oxidised. Do not use if discoloured (e.g. pink, dark yellow, brown) or if there is a precipitate.
|
|